Literature DB >> 7511146

Protection of transforming growth factor-beta 1 activity by heparin and fucoidan.

T A McCaffrey1, D J Falcone, D Vicente, B Du, S Consigli, W Borth.   

Abstract

The transforming growth factor-beta (TGF-beta) family of proteins exert diverse and potent effects on proliferation, differentiation, and extracellular matrix synthesis. However, relatively little is known about the stability or processing of endogenous TGF-beta activity in vitro or in vivo. Our previous work indicated that 1) TGF-beta 1 has strong heparin-binding properties that were not previously recognized because of neutralization by iodination, and 2) heparin, and certain other polyanions, could block the binding of TGF-beta 1 to alpha 2-macroglobulin (alpha 2-M). The present studies investigated the influence of heparin-like molecules on the stability of the TGF-beta 1 signal in the pericellular environment. The results indicate that heparin and fucoidan, a naturally occurring sulfated L-fucose polymer, suppress the formation of an initial non-covalent interaction between 125I-TGF-beta 1 and activated alpha 2-M. Electrophoresis of 125I-TGF-beta 1 showed that fucoidan protects TGF-beta 1 from proteolytic degradation by plasmin and trypsin. While plasmin caused little, if any, activation of latent TGF-beta derived from vascular smooth muscle cells (SMC), plasmin degraded acid-activated TGF-beta, and purified TGF-beta 1, and this degradation was inhibited by fucoidan. In vitro, heparin and fucoidan tripled the half-life of 125I-TGF-beta 1 and doubled the amount of cell-associated 125I-TGF-beta 1. Consistent with this protective effect, heparin- and fucoidan-treated SMC demonstrated elevated levels of active, but not latent, TGF-beta activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511146     DOI: 10.1002/jcp.1041590108

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  21 in total

1.  Manipulation of hydrogel assembly and growth factor delivery via the use of peptide-polysaccharide interactions.

Authors:  Le Zhang; Eric M Furst; Kristi L Kiick
Journal:  J Control Release       Date:  2006-06-10       Impact factor: 9.776

Review 2.  Inflammation and Alzheimer's disease.

Authors:  H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

Review 3.  Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.

Authors:  Rajendra Gharbaran
Journal:  Tumour Biol       Date:  2016-06-18

4.  Fucoidan promotes early step of cardiac differentiation from human embryonic stem cells and long-term maintenance of beating areas.

Authors:  Sofiane Hamidi; Didier Letourneur; Rachida Aid-Launais; Antonio Di Stefano; William Vainchenker; Françoise Norol; Catherine Le Visage
Journal:  Tissue Eng Part A       Date:  2014-02-14       Impact factor: 3.845

5.  A polyelectrolyte multilayer platform for investigating growth factor delivery modes in human liver cultures.

Authors:  Christine Lin; Raimundo Romero; Lioudmila V Sorokina; Kimberly R Ballinger; Laura W Place; Matt J Kipper; Salman R Khetani
Journal:  J Biomed Mater Res A       Date:  2017-12-04       Impact factor: 4.396

Review 6.  Proteoglycans: pericellular and cell surface multireceptors that integrate external stimuli in the mammary gland.

Authors:  M Delehedde; M Lyon; N Sergeant; H Rahmoune; D G Fernig
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.673

7.  Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1.

Authors:  T A McCaffrey; S Consigli; B Du; D J Falcone; T A Sanborn; A M Spokojny; H L Bush
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

8.  Interactions between growth factors and integrins: latent forms of transforming growth factor-beta are ligands for the integrin alphavbeta1.

Authors:  J S Munger; J G Harpel; F G Giancotti; D B Rifkin
Journal:  Mol Biol Cell       Date:  1998-09       Impact factor: 4.138

9.  Transforming growth factor-beta1 induces heparan sulfate 6-O-endosulfatase 1 expression in vitro and in vivo.

Authors:  Xinping Yue; Xian Li; Hong T Nguyen; Dawn R Chin; Deborah E Sullivan; Joseph A Lasky
Journal:  J Biol Chem       Date:  2008-05-23       Impact factor: 5.157

10.  Soluble and membrane-bound TGF-β-mediated regulation of intratumoral T cell differentiation and function in B-cell non-Hodgkin lymphoma.

Authors:  Zhi-Zhang Yang; Deanna M Grote; Steven C Ziesmer; Bing Xiu; Nicole R Yates; Frank J Secreto; Lucy S Hodge; Thomas E Witzig; Anne J Novak; Stephen M Ansell
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.